- Home
- CRMD vs IGD Comparison
CRMD vs IGD Comparison
Compare CRMD & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRMD | IGD |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.7M | 516.6M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRMD | IGD |
|---|---|---|
| Price | $7.75 | $6.40 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $15.33 | N/A |
| AVG Volume (30 Days) | ★ 936.1K | 325.6K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $8.13 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $5.58 |
| 52 Week High | $13.02 | $6.74 |
Technical Indicators
Market Signals| Indicator | CRMD | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 57.36 |
| Support Level | $7.08 | $5.97 |
| Resistance Level | $9.01 | $6.61 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 97.18 | 97.59 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.